Literature DB >> 15206943

Amino acids at the N- and C-termini of human glutamate carboxypeptidase II are required for enzymatic activity and proper folding.

Cyril Barinka1, Petra Mlcochová, Pavel Sácha, Ivan Hilgert, Pavel Majer, Barbara S Slusher, Václav Horejsí, Jan Konvalinka.   

Abstract

Human glutamate carboxypeptidase II (GCPII) is a co-catalytic metallopeptidase and its putative catalytic domain is homologous to the aminopeptidases from Vibrio proteolyticus and Streptomyces griseus. In humans, the enzyme is expressed predominantly in the nervous system and the prostate. The prostate form, termed prostate-specific membrane antigen, is overexpressed in prostate cancer and is used as a diagnostic marker of the disease. Inhibition of the form of GCPII expressed in the central nervous system has been shown to protect against ischemic injury in experimental animal models. Human GCPII consists of 750 amino acids, and six individual domains were predicted to constitute the protein structure. Here, we report the analysis of the contribution of these putative domains to the structure/function of recombinant human GCPII. We cloned 13 mutants of human GCPII that are truncated or extended at one or both the N- and C-termini of the GCPII sequence. The clones were used to generate stably transfected Drosophila Schneider's cells, and the expression and carboxypeptidase activities of the individual protein products were determined. The extreme C-terminal region of human GCPII was found to be critical for the hydrolytic activity of the enzyme. The deletion of as few as 15 amino acids from the C-terminus was shown to completely abolish the enzymatic activity of GCPII. Furthermore, the GCPII carboxypeptidase activity was abrogated upon removal of more than 60 amino acid residues from the N-terminus of the protein. Overall, these results clearly show that amino acid segments at the N- and C-termini of the ectodomain of GCPII are essential for its carboxypeptidase activity and/or proper folding.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15206943     DOI: 10.1111/j.1432-1033.2004.04209.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  11 in total

1.  Structural and biochemical characterization of the folyl-poly-γ-l-glutamate hydrolyzing activity of human glutamate carboxypeptidase II.

Authors:  Michal Navrátil; Jakub Ptáček; Pavel Šácha; Jana Starková; Jacek Lubkowski; Cyril Bařinka; Jan Konvalinka
Journal:  FEBS J       Date:  2014-06-17       Impact factor: 5.542

2.  Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase.

Authors:  Mindy I Davis; Melanie J Bennett; Leonard M Thomas; Pamela J Bjorkman
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-18       Impact factor: 11.205

3.  Development of a high-throughput fluorescence polarization assay to identify novel ligands of glutamate carboxypeptidase II.

Authors:  Glenda Alquicer; David Sedlák; Youngjoo Byun; Jirí Pavlícek; Marigo Stathis; Camilo Rojas; Barbara Slusher; Martin G Pomper; Petr Bartunek; Cyril Barinka
Journal:  J Biomol Screen       Date:  2012-06-29

4.  Membrane Protein Dimerization in Cell-Derived Lipid Membranes Measured by FRET with MC Simulations.

Authors:  Jan Škerle; Jana Humpolíčková; Nicholas Johnson; Petra Rampírová; Edita Poláchová; Monika Fliegl; Jan Dohnálek; Anna Suchánková; David Jakubec; Kvido Strisovsky
Journal:  Biophys J       Date:  2020-03-29       Impact factor: 4.033

5.  Expression and distribution of 'high affinity' glutamate transporters GLT1, GLAST, EAAC1 and of GCPII in the rat peripheral nervous system.

Authors:  Valentina Alda Carozzi; Annalisa Canta; Norberto Oggioni; Cecilia Ceresa; Paola Marmiroli; Jan Konvalinka; Chiara Zoia; Mario Bossi; Carlo Ferrarese; Giovanni Tredici; Guido Cavaletti
Journal:  J Anat       Date:  2008-11       Impact factor: 2.610

6.  Structural characterization of P1'-diversified urea-based inhibitors of glutamate carboxypeptidase II.

Authors:  Jiri Pavlicek; Jakub Ptacek; Jiri Cerny; Youngjoo Byun; Lubica Skultetyova; Martin G Pomper; Jacek Lubkowski; Cyril Barinka
Journal:  Bioorg Med Chem Lett       Date:  2014-03-28       Impact factor: 2.823

7.  Structure-Activity Relationship of (18)F-Labeled Phosphoramidate Peptidomimetic Prostate-Specific Membrane Antigen (PSMA)-Targeted Inhibitor Analogues for PET Imaging of Prostate Cancer.

Authors:  Shorouk Dannoon; Tanushree Ganguly; Hendry Cahaya; Jonathan J Geruntho; Matthew S Galliher; Sophia K Beyer; Cindy J Choy; Mark R Hopkins; Melanie Regan; Joseph E Blecha; Lubica Skultetyova; Christopher R Drake; Salma Jivan; Cyril Barinka; Ella F Jones; Clifford E Berkman; Henry F VanBrocklin
Journal:  J Med Chem       Date:  2016-06-13       Impact factor: 7.446

8.  Design of composite inhibitors targeting glutamate carboxypeptidase II: the importance of effector functionalities.

Authors:  Zora Novakova; Jiri Cerny; Cindy J Choy; Jessie R Nedrow; Joeseph K Choi; Jacek Lubkowski; Clifford E Berkman; Cyril Barinka
Journal:  FEBS J       Date:  2015-11-05       Impact factor: 5.542

9.  Co-expression and impact of prostate specific membrane antigen and prostate specific antigen in prostatic pathologies.

Authors:  Awatef Ben Jemaa; Yosra Bouraoui; Sataa Sallami; Ahmed Banasr; Nawfel Ben Rais; Latifa Ouertani; Yassin Nouira; Ali Horchani; Ridha Oueslati
Journal:  J Exp Clin Cancer Res       Date:  2010-12-28

Review 10.  Targeted Radionuclide Therapy of Prostate Cancer-From Basic Research to Clinical Perspectives.

Authors:  Malwina Czerwińska; Aleksander Bilewicz; Marcin Kruszewski; Aneta Wegierek-Ciuk; Anna Lankoff
Journal:  Molecules       Date:  2020-04-10       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.